Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III telaprevir retreatment trial in prior peginterferon/ribavirin failures with delayed-start comparison
2008-000533-22Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telaprevir in hepatitis C virus infection and Hepatitis C genotype 1 (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Sustained virologic response, Superiority in prior non-responder stratum and 1 more. Started Jul 2008; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infectionHepatitis C genotype 1
Beyond the preview
Go deeper on 2008-000533-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000533-22.